Table 2.
Mortality and safety endpoints in the safety population
| Zilucoplan | Control | |
|---|---|---|
| no. (%) | no. (%) | |
| Number of patients | 54 | 24 |
| Mortality | ||
| All-cause mortality at day 28 | 5 (9) | 5 (21) |
| All-cause mortality at 12–22 weeks | 7 (13) | 5 (21) |
| Serious adverse events (SAEs) | ||
| Incidence of SAEs at day 28 | 7 (13) | 5 (21) |
| Incidence of SAEs at 12–22 weeks | 10 (19) | 5 (21) |
| All SAEs leading to mortality at 12–22 weeks | ||
| Covid-19 | 4 (7) | 3 (13) |
| Infectious disorder (not COVID-19) | 2 (4) | 1 (4) |
| Thrombosis | 0 | 1 (4) |
| Multi-organ failure | 1 (2) | 0 |
| All SAEs not leading to mortality at 12–22 weeks* | ||
| Infectious disorder (not COVID-19) | 3 (6) | 0 |
| Acute kidney injury | 1 (2) | 1 (4) |
| Cardiac disorder | 1 (2) | 0 |
| Nosocomial or invasive fungal infectiona | ||
| Incidence at day 28 | 10 (19) | 4 (17) |
| Adverse events | ||
| Incidence at day 28 | 39 (72) | 17 (71) |
| Adverse events with incidence > 10% | ||
| Constipation | 7 (13) | 5 (21) |
| Hypertension | 8 (15) | 2 (8) |
SAE serious adverse events, COVID-19 coronavirus disease 2019
*Progression and symptoms of COVID-19 were excluded from reporting
aRequiring treatment